Gene · 572
Papers1,939
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,939
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Kaempferol: A potential agent in the prevention of colorectal cancer. | Physiol Rep | 2022 | 36259115 | PubTator, text mining | PubMed |
| [Effects of arsenic and its main metabolites on A549 cell apoptosis and the expression of pro-apoptotic genes Bad and Bik]. | Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi | 2022 | 36229210 | PubTator, text mining | PubMed |
| Inhibition of mTOR signaling protects human glioma cells from hypoxia-induced cell death in an autophagy-independent manner. | Cell Death Discov | 2022 | 36202792 | PubTator, text mining | PubMed |
| B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers. | Mol Cancer Res | 2022 | 36166198 | PubTator, text mining | PubMed |
| Co-Stimulatory Receptor Signaling in CAR-T Cells. | Biomolecules | 2022 | 36139142 | PubTator, text mining | PubMed |
| Organoid-on-a-chip model of human ARPKD reveals mechanosensing pathomechanisms for drug discovery. | Sci Adv | 2022 | 36129975 | PubTator, text mining | PubMed |
| The effect of two types of diet on apoptosis indexes, lipid profile and histopathological outcome in acute kidney injury during exercise. | BMC Nephrol | 2022 | 36123655 | PubTator, text mining | PubMed |
| Curcumin against gastrointestinal cancer: A review of the pharmacological mechanisms underlying its antitumor activity. | Front Pharmacol | 2022 | 36120367 | PubTator, text mining | PubMed |
| A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors. | Explor Target Antitumor Ther | 2022 | 36071980 | PubTator, text mining | PubMed |
Kaempferol prevents angiogenesis of rat intestinal microvascular endothelial cells induced by LPS and TNF-α via inhibiting VEGF/Akt/p38 signaling pathways and maintaining gut-vascular barrier integrity. | Chem Biol Interact | 2022 | 36049518 | PubTator, text mining | PubMed |
| Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk. | Cancer Cell Int | 2022 | 35986321 | PubTator, text mining | PubMed |
| Preserving and rejuvenating old organs for transplantation: novel treatments including the potential of senolytics. | Curr Opin Organ Transplant | 2022 | 35950886 | PubTator, text mining | PubMed |
| Recent advances in the therapeutic efficacy of hepatocyte growth factor gene-modified mesenchymal stem cells in multiple disease settings. | J Cell Mol Med | 2022 | 35922965 | PubTator, text mining | PubMed |
| Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors. | Int J Oncol | 2022 | 35920189 | PubTator, text mining | PubMed |
| Andrographolide inhibits the growth of human osteosarcoma cells by suppressing Wnt/β-catenin, PI3K/AKT and NF-κB signaling pathways. | Chem Biol Interact | 2022 | 35917943 | PubTator, text mining | PubMed |
| Stimulation of adenosine A1 receptor prevents oxidative injury in H9c2 cardiomyoblasts: Role of Gβγ-mediated Akt and ERK1/2 signaling. | Toxicol Appl Pharmacol | 2022 | 35901927 | PubTator, text mining | PubMed |
| Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases. | Int J Mol Sci | 2022 | 35897658 | PubTator, text mining | PubMed |
| The Role of PIM Kinases in Pediatric Solid Tumors. | Cancers (Basel) | 2022 | 35892829 | PubTator, text mining | PubMed |
| Viral Encoded miRNAs in Tumorigenesis: Theranostic Opportunities in Precision Oncology. | Microorganisms | 2022 | 35889167 | PubTator, text mining | PubMed |
| Natural Products of Marine Origin for the Treatment of Colorectal and Pancreatic Cancers: Mechanisms and Potential. | Int J Mol Sci | 2022 | 35887399 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/572/papers?page=7